Heidi B. Capozzi compensation by year
CVS HEALTH Summary Compensation Table · the one fiscal year held| Component | FY2024 |
|---|---|
| Salary | $265,625 |
| Bonus | $1,500,000 |
| Stock awards | $4,999,989 |
| Option awards | $0 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $85,134 |
| Total | $6,850,748 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CVS HEALTH Corp DEF 14A filed April 4, 2025, accession 0001308179-25-000386, and prior-year filings.
How this page was built: the CVS HEALTH Corp filed document, accession 0001308179-25-000386. Every figure is read from that document and cited to the page and table it appears in. Filed April 4, 2025.
Insider transactions since the last proxy
8 Form 4 lines since the FY2024 proxy (filed April 4, 2025)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| — | — | — | — | — | 5 |
| 2026-04-01 | Tax withholding | — | 1,334 | $72.49 | 13,023 |
| 2026-03-31 | Grant or award | — | 10,025 | $71.82 | 84,450 |
| 2026-03-31 | Grant or award derivative | — | 64,670 | $71.82 | 64,670 |
| 2025-11-30 | Tax withholding | — | 9,470 | $80.36 | 11,415 |
| 2024-10-23 | Purchase | — | 35 | $56.85 | 85 |
| 2024-10-02 | Purchase | — | 10 | $62.24 | 50 |
| 2024-09-09 | Purchase | — | 35 | $56.47 | 40 |
The 8 most recent of 8 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments CVS HEALTH discloses, by trigger · FY2024| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and involuntary termination | $1,275,000 | $3,750,200 | $7,122 | $5,032,322 |
| Involuntary termination without cause | $1,275,000 | $937,528 | $7,122 | $2,219,650 |
| Involuntary for cause | $0 | $-3,750,200 | $0 | $-3,750,200 |
| Death | $0 | $3,750,200 | $0 | $3,750,200 |
| Voluntary resignation | $0 | $0 | $0 | $0 |
Per the Potential Payments Upon Termination or Change in Control table in CVS HEALTH Corp's FY2024 proxy. Estimates as the company printed them; a dash means it printed no figure.
CVS HEALTH’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Karen S. Lynch | Former President and Chief Executive Officer | $23,431,466 |
| J. David Joyner | President and Chief Executive Officer | $17,808,792 |
| Prem S. Shah | Executive Vice President and Group President | $13,265,855 |
| Tilak Mandadi | Executive Vice President Ventures, and Chief Digital, Data, Analytics and Technology Officer | $11,361,343 |
| Thomas F. Cowhey | Executive Vice President and Chief Financial Officer | $7,644,364 |
| Heidi B. Capozzi · this page | Executive Vice President and Chief People Officer | $6,850,748 |
The full CVS HEALTH compensation record
free company briefThis page is one person within CVS HEALTH's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the CVS HEALTH proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CVS HEALTH's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.